Ligand Pharmaceuticals (LGND) Acquisitions (2011 - 2024)

Ligand Pharmaceuticals (LGND) posted Acquisitions of -$92.0 million for Q4 2024, down 124.34% sequentially from $378.0 million in Q4 2020.

Ligand Pharmaceuticals (LGND) Acquisitions (2011 - 2024) Analysis & Trends

Ligand Pharmaceuticals has reported Acquisitions for 7 years, with the latest figure at -$92.0 million in Q4 2024.

Quarterly Acquisitions changed N/A year-over-year to -$92.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$92.0 million (changed N/A YoY) and the FY2023 annual result came in at $10.4 million, changed N/A from the prior year.
Acquisitions slipped to -$92.0 million in Q4 2024 per LGND's latest filing, from $378.0 million in the prior quarter.
Over five years, Acquisitions peaked at $378.0 million in Q4 2020 and troughed at -$92.0 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Ligand Pharmaceuticals	5.87 Bn	4.51 Bn	60.48 Mn	-

Download Data